Deferred Tax Assets, Valuation Allowance of Viking Therapeutics, Inc. from 31 Dec 2014 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Viking Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2014 to 31 Dec 2025.
  • Viking Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $264,737,000, a 61% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Viking Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $264,737,000 +$100,674,000 +61% 31 Dec 2025 10-K 11 Feb 2026 2025 FY
Q4 2024 $164,063,000 +$45,106,000 +38% 31 Dec 2024 10-K 11 Feb 2026 2025 FY
Q4 2023 $118,957,000 +$29,088,000 +32% 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q4 2022 $89,869,000 +$22,091,000 +33% 31 Dec 2022 10-K 26 Feb 2025 2024 FY
Q4 2021 $67,778,000 +$17,462,000 +35% 31 Dec 2021 10-K 07 Feb 2024 2023 FY
Q4 2020 $50,316,000 +$12,724,000 +34% 31 Dec 2020 10-K 09 Feb 2022 2021 FY
Q4 2019 $37,592,000 +$7,833,000 +26% 31 Dec 2019 10-K 17 Feb 2021 2020 FY
Q4 2018 $29,759,000 +$8,983,000 +43% 31 Dec 2018 10-K 26 Feb 2020 2019 FY
Q4 2017 $20,776,000 -$1,339,992 -6.1% 31 Dec 2017 10-K 13 Mar 2019 2018 FY
Q4 2016 $22,115,992 +$4,393,461 +25% 31 Dec 2016 10-K 07 Mar 2018 2017 FY
Q4 2015 $17,722,531 +$9,318,911 +111% 31 Dec 2015 10-K 21 Mar 2017 2016 FY
Q4 2014 $8,403,620 31 Dec 2014 10-K 08 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.